Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$28.04 +0.47%

+$0.16 today

Market cap
$2.20B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.52M

Average 0.94M

CLDX Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Celldex Therapeutics, Inc.NASDAQ: CLDX

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin not reported for Q3 FY2026

Over 3 fiscal years it narrowed by 14271.0 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 8 analysts of -21296.1% for the fiscal year ending Dec 2026, down from -19160.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
-19160.0%-16381.1 pp YoY
LTMSep 2026
-298657.1%-288801.8 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter—+110989.9 pp—
1 year-16381.1 pp-2136.1 pp+14245.0 pp
3 years-14271.0 pp+18954.2 pp+33225.2 pp
5 years+19195.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-19160.0%
Year-over-year change
-16381.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How CLDX compares with its peers on the latest reported figures

  • CLDX's LTM Sep 2026 operating margin of -298657.1% is the lowest of the 9 companies compared; the peer median is -123.2%.
  • Its year-over-year change of -288801.8 pp is the lowest of 8, against a peer median of +95.9 pp.
  • Over three fiscal years its change of -14271.0 pp compares with a peer median of +135.8 pp.
CLDX Competitors Peer median
Operating Margin for CLDX and competitors
Company Period LTM level YoY 3-year change
CGENCompugen Ltd.LTM Mar 202642.3% +95.9 pp+514.7 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202641.3% +360.6 pp+135.8 pp
AGENAgenus Inc.LTM Mar 20266.6% +108.0 pp+165.0 pp
MGNXMacroGenics, Inc.LTM Mar 2026-40.5% +24.7 pp+32.2 pp
XNCRXencor, Inc.LTM Jun 2026-205.8% -128.2 pp-91.2 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-415.4% -286.4 pp+93.7 pp
IMNMImmunome, Inc.FY2025-3084.8% +297.6 pp—
ADAGAdagene Inc.LTM Jun 2024-4534.8% —+623.6 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-298657.1% -288801.8 pp-14271.0 pp
VRXAVeraxa Biotech Holding AG—— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding CLDX) -123.2%+95.9 pp+135.8 pp

Competitors are the stored peer set for CLDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.65M2.36M6.88M7.02M1.5M
Cost of Revenue53.31M82.26M118.01M163.55M0
Gross Profit(48.66M)(79.9M)(111.13M)(156.53M)1.5M
Gross Margin-1046.2%-3389.9%-1614.5%-2229.8%100.0%
Research & Development56.81M82.26M118.01M163.55M245.1M
Selling, General & Admin20.49M27.2M30.91M38.55M43.8M
Operating Expenses22.58M35.33M43.41M38.55M288.9M
Depreciation & Amortization3.07M2.9M3.01M3.18M3.38M
EBITDA(66.08M)(104.2M)(139.03M)(154.69M)(255.42M)
EBITDA Margin-1420.8%-4420.9%-2020.0%-2203.5%-17028.0%
Operating Income(71.24M)(115.23M)(154.54M)(195.08M)(287.4M)
Operating Margin-1531.8%-4889.0%-2245.3%-2778.9%-19160.0%
Interest Income505K2.91M13.11M37.22M28.61M
Interest Expense00000
Other Income / Expenses505K2.91M13.11M37.22M28.6M
Income Before Tax(70.74M)(112.33M)(141.43M)(157.86M)(258.8M)
Pre-Tax Margin-1520.9%-4765.6%-2054.8%-2248.8%-17253.3%
Income Tax Expense(227K)0000
Net Income(70.51M)(112.33M)(141.43M)(157.86M)(258.8M)
Net Margin-1516.0%-4765.6%-2054.8%-2248.8%-17253.3%
EPS (Basic)(1.64)(2.40)(2.92)(2.45)(3.90)
EPS (Diluted)(1.64)(2.40)(2.92)(2.45)(3.90)
Weighted Avg Shares42.87M46.89M48.45M64.4M66.5M
Weighted Avg Shares (Diluted)42.87M46.89M48.45M64.4M66.5M

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Intrinsic Alpha fair value

Locked

Current Price

$28.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.